Oscient Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oscient Pharmaceuticals Corporation
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.